U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H34FN5O2
Molecular Weight 479.5896
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-0773

SMILES

CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCC5=NC6=NC=CC=C6N5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O

InChI

InChIKey=GBEUKTWTUSPHEE-JWJWXJQQSA-N
InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1

HIDE SMILES / InChI

Description

MK-0773 is an orally active selective androgen receptor modulator. The safety and efficacy of MK-0773 was evaluated in sarcopenic elderly women. The MK-0773- induced improvements in lean body mass were not accompanied by statistically significant improvements in physical function. Higher dose of MK-0773 or longer duration of therapy might have resulted in improvements in physical function, but liver transaminase elevations likely preclude further development of MK-0773. Drug-candidate had been in phase I clinical trials for the treatment of osteoporosis.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.6 nM [IC50]
49.5 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Primary
PubMed

PubMed

TitleDatePubMed
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology.
2010 May 28
A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.
2013
Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
2013 Dec
Identification of selected in vitro generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes.
2016
Detection of SARMs in doping control analysis.
2018 Mar 15
Patents

Sample Use Guides

In Vivo Use Guide
50 mg twice daily, 6 month treatment period
Route of Administration: Oral
In Vitro Use Guide
The affinity of MK-0773 for AR across species was evaluated using COS cells transfected with AR, and IC50 values were very similar in four species (rat, 0.50 nM; dog, 0.55 nM; rhesus, 0.45 nM; human, 0.65 nM).
Name Type Language
MK-0773
Common Name English
PF-05314882
Code English
N-(3H-IMIDAZO(4,5-B)PYRIDIN-2-YLMETHYL)-2-FLUORO-4-METHYL-3-OXO-4-AZA-5.ALPHA.-ANDROST-1-ENE-17.BETA.-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
ChEMBL
CHEMBL3545333
Created by admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
PRIMARY
PUBCHEM
11950726
Created by admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
PRIMARY
CAS
606101-58-0
Created by admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
PRIMARY
WIKIPEDIA
MK-0773
Created by admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
PRIMARY